ArticleInternational journal of molecular sciences2022
Production and Characterization of Peptide Antibodies to the C-Terminal of Frameshifted Calreticulin Associated with Myeloproliferative Diseases.
Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Review
- Challenges in the Evolving Role of Calreticulin as a Promising Target for Precision Medicine in Myeloproliferative Neoplasms.Cancers · 2025Review
- Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications.Current hematologic malignancy reports · 2025Review
- Characterization of Peptide Antibodies by Epitope Mapping Using Resin-Bound and Soluble Peptides.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Sequential Double Immunoblotting with Peptide Antibodies.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Peptide Antibodies: Current Status.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Fmoc Solid-Phase Peptide Synthesis.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Production of Antibodies to Peptide Targets Using Hybridoma Technology.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis.Nature communications · 2023Article
- Subtractive panning for the isolation of monoclonal PEPITEM peptide antibody by phage display.Scientific reports · 2023Article
- Advances in Antibody Design and Antigenic Peptide Targeting 2.0.International journal of molecular sciences · 2023Article
- Determination of crucial epitopes in the sperm protein calsperin employing synthetic peptides and monoclonal antibodies.Journal of peptide science : an official publication of the European Peptide Society · 2023Article
- Design, Production, Characterization, and Use of Peptide Antibodies.Antibodies (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myeloproliferative Neoplasms (MPNs) constitute a group of rare blood cancers that are characterized by mutations in bone marrow stem cells leading to the overproduction of erythrocytes, leukocytes, and thrombocytes. Mutations in
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.